A Novel Crosslinking Strategy for MS Structural Biology

Lead Research Organisation: Newcastle University
Department Name: Inst for Cell and Molecular Biosciences

Abstract

Proteins may be thought of as the essential 'factories' within living cells. They are intricate and complex in construction, and carry out a variety of functions essential for the existence of life. Understanding the inner workings of these factories requires knowledge of how they are assembled, both at the atomic level and at the level of higher-order multi-complex protein entities that perform essential functions, such as respiration and cell replication. Protein factories are dynamic structures, responding to input signals through interactions with other molecules, most frequently other proteins. Knowing what happens during the processing of signals and how output responses are generated relies on knowledge of both the protein 3D structure and any dynamic changes that take place to it at the molecular-level during such events.
A deeper understanding of how one protein recognises and binds to another protein in order to regulate its function underpins most of the biological activity in living cells and is therefore crucial to how we may go about designing new molecules to prevent or enhance such interactions. Any advancement in our understanding of protein-protein interactions has the potential to widen the number of targets for modifying biological function by the use of drugs. Such knowledge may help to accelerate the development of new molecular medicines to treat most of our major serious diseases, as these often manifest themselves through protein interaction pathways.
Structural biology is concerned with the study of protein 'shape' and how alterations in shape affect function. Structures ranging from individual proteins to large multicomponent cellular assemblies are studied. This challenging problem requires the integration of many different biophysical and biochemical protein analysis techniques. One comparatively recent technique to be applied to the problem of determining the spatial relationships between proteins in a complex or in close proximity through a binding event is the use of chemical cross-linking followed mass spectrometry analysis (XL-MS).
Chemical cross-linking seeks to 'freeze' the 3D arrangement of protein chains in a complex by tethering them together using a reagent that forms a strong covalent link between adjacent regions, provided they fall within the distance of the span of the cross-linker. The covalently-linked regions of the proximal protein chains can then be excised from the protein backbone using an enzyme and the cross-linked complex carrying residues of both parent proteins analysed using mass spectrometry (MS). Modern MS can break these linked fragments into smaller pieces and determine their constituent amino acid residues. Using clever software algorithms we can decipher not only the identity of the two linked proteins that were in close proximity, but also ID the actual sites of linkage. This increases the resolution of this method for structure determination from the level of large protein domains down to even smaller sections, dubbed ''peptide-level resolution''. Better resolution in turn permits us to build better, more accurate models of the structures of multi-protein complexes.
Unfortunately XL-MS in its present format exhibits a number of weaknesses. Current cross-linkers in general use are non-cleavable. This gives rise to large linked complexes upon excision that are tricky to analyse by MS due to their size and complex fragmentation patterns. Also XL-MS reagents tend not to react efficiently, making the linked peptides difficult to detect in protein digests.
To tackle these current limiting issues we propose the introduction of an entirely new innovative cross-linking and MS analysis strategy that involves developing a novel class of cross-linking reagents which will allow detection of the linked peptides combined with simple automated MS data analysis.

Technical Summary

Integrative structural biology seeks to compute models of multicomponent protein assemblies using proximity constraints derived from a variety of data sets including chemical cross-linking mass spectrometry [XL-MS].
MS, reaction protocols, and XL-MS spectral analysis algorithms have advanced, such that XL-MS is now a key technique, particularly in situations that have proved challenging by other methods. Despite such developmental strides, XL-MS has struggled to come of age and current application is often limited to specialist labs. This is chiefly because XL-MS poses several technical challenges. This project aims to tackle the current limiting issues:
1. Enrichment of low abundance cross-linked peptide species from highly complex protease digests of cross-linked protein-protein interaction partners.
2. Circumvention of the analytical challenges currently associated with chromatographic analysis of high charge-state, high-mass cross-linked peptide species.
3. Provision of a means to discriminate between desired and undesired cross-linked peptide species.
4. Enablement of interpretation of complex MS/MS fragmentation spectra of cross-linked species using universal proteomic identification tools.
These issues will be addressed herein through development of a novel class of cross-linking reagents which will enable, post-digestion enrichment, detection of the correct end-products and automated LC/MS analysis. This will result in a new, easy to use, scientifically powerful XL-MS approach.

Planned Impact

Our aim here is to demonstrate a significant improvement in the performance of the cross-linking mass spectrometry technique, with the ultimate aim of new tool provision. This research project however is aimed not only at improving the methodology of cross-linking mass spectrometry in the short-term, but at enabling significant advancement in our scientific understanding of protein-protein interactions in the longer-term, through the application of our gained knowledge and dissemination of our developed tools and protocols.

As such, the immediate impact of this work will be of benefit to the following different groups:
1. First is the impact on the wider scientific community of this new strategy, improving the quality and availability for scientists of key information about important proteome interactions. The ability to access this information, will both enhance our understanding and inform new experiments; as well as giving the UK research base a competitive edge and enhancing its international reputation.
2. Secondly the development of a significantly improved technology platform for interaction analysis will benefit not just UK researchers, but will also be widely adopted by many groups in the international biological sciences community where there is a need to understand one of the many cellular processes that are mediated by stable protein complexes.
3. With regard to UK business, this technology will appeal to many researchers in the pharmaceutical, agrochemical and biologics industries where the analysis of protein interactions is required for the discovery of druggable protein targets. This is important in the development of biologically active small molecules with novel mode of action, such as drugs, pesticides and herbicides, critical to the economic success of these companies. The consequence of having access to tools accelerating scientific discovery and maximising the information attainable from studying protein interactions will improve the competitiveness of UK research based companies.
4. This proposal will give rise to primary IP with the potential for technology exploitation through licensing agreements, thereby providing a regional/national economic impact through engagement and/or collaboration with industrial partners, e.g. commercialisation of tools, reagents and techniques. [See attached letters of interest].

Finally, this technology tool has the potential to offer significant insight into basic biological interaction mechanisms relevant to understanding the aetiology of, or the development of treatments for many common serious diseases or conditions, with the consequent potential impact to enhance the quality of health/life for everyone.

Publications

10 25 50
 
Description This Tools and Resources Development Fund (TRDF) one year 'proof-of-concept' award into the development of 'A Novel Crosslinking Strategy for MS Structural Biology' has provided us with the funding to proof-of-concept, prototype and elaborate our novel tagging technology into a new paradigm for capturing protein-protein interactions (PPIs) as follows:
1. Enabled development of a prototype tagging methodology that displays highly specific (i.e. amino acid targeted) protein tagging.
2. The tagging supports mild chemical reaction conditions (e.g. phosphate buffer, pH 7.4) that permit capture of proteins (and their interaction partners) at neutral / near neutral pH, considered relatively benign for most protein-protein interactions.
3. The (chemical) tag cleavage mechanism has been designed to release protein (& interaction partners) under similarly mild conditions (~pH 8, bicarbonate buffer).
In addition to capturing protein-protein interactions, this technology also shows promise in providing a new way to specifically (i.e. chemically) capture and release recombinant proteins under very mild (buffered) conditions that should preserve functionality and structure.
At this time no chemical method for expressed protein purification exists, and so we can offer the first new 'class' of tool in the protein engineer's toolbox for a generation. All current tag purification methodologies on the market are based upon co-expressed amino acid fusion tags (such as polyhistidine, GST, FLAG, Strep-tag etc.) coupled with affinity capture and related elution chromatography. Affinity elution of tagged protein (the current norm) is replaced here by a mild chemical cleavage which serves to enrich the product without the need for increased stringency washes, a feature that provides new options for protein capture and release.
Thanks to the backing of BBSRC and the TRDF we have been able to secure follow-on funding for this tag development project via the north east England regional Northern Accelerator Programme (Research England) in order to continue our studies into capturing proteins and protein-protein interactions using our novel tagging technology. We plan to be in a position to secure IP for our platform by the end 2020 / early 2021.
Exploitation Route o Protein-protein interactions are intrinsic to all biological processes, including those that play a crucial role in both normal physiology and disease. Their study is therefore critical for gaining a deep understanding of all biochemical mechanisms.
Since the knowledge on what kinds of protein complexes can be physiologically formed cannot be obtained directly from genomic information, there is a need to investigate experimentally the combinations that actually make up protein complexes. This is where we believe our novel chemistry offers a 'new paradigm' because of the capability to capture (and release) protein-protein interactions under mild conditions. This should in turn help drive forward the work of researchers in advancing our knowledge of biological processes relating to both health and disease for the benefit and wellbeing of society.

o With the rapid rise in blockbuster biologics to treat and manage a range of conditions from autoimmune diseases to cancers, the bioprocess (manufacture) of such complex molecules becomes 'the' valuable IP for companies. Most biologics are protein-based drugs produced using recombinant DNA technology. They dominate the top-selling drugs lists with the current market estimated to be valued between US$220bn and US$300bn per annum and still growing steadily. We believe our novel tag can be applied to purification pipelines as part of the final polish process to generate product for in vivo human use. With the help of this award we have been able to prototype, for the first time, a novel, chemistry-based method of tagging and releasing that can be applied to recombinant proteins under relatively benign conditions (i.e. bicarbonate buffer, pH 8) with and without interaction partners. o Using our TRDF generated POC data, we have been able to engage in several discussions with a regional private sector business, the Centre for Process Innovation (CPI), Wilton and Cleveland, UK. Our discussions with CPI have mainly surrounded the possible applications of an immobilised (bead) form our tagging technology to bioprocessing, specifically biologics. Given the strong regional presence of bioprocessing companies such as Fujifilm Diosynth (Billingham, Stockton-on-Tees) and the importance (both clinically and economically) of the biologics market, we feel that our product enrichment technology may be able to offer biopharma companies an 'edge' regarding their processes for the manufacture of certain difficult-to-purify protein / complex products.

o Finally, with future funding, we have one further ambition to adapt our tagging technology towards expanding conventional immuno-PCR arrays away from dyes into a newer, tag-based, multiplexed, multivariate diagnostics array platform, with significant impacts on human health relating to early diagnosis, monitoring health and well-being, as well as providing opportunities for wealth creation through economic benefits via IP, investment and licencing.


The tagging and crosslinking chemistry we have developed as part of this project should find applications within both the research and biotechnology sectors.
Our targeted labelling and mild release chemistry for protein modification / crosslinking should find applications in areas such as the selective purification of recombinant proteins and biologics because of the novel capability to bypass conventional sequence (i.e. expressed) protein tags. Additionally there should be applications in targeted pull-down (and release) along with crosslinking uses for the analysis of protein complexes in R&D.
Sectors Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology

 
Description Thanks to the backing of BBSRC and the TRDF we have been able to secure follow-on funding for this tag development project via the north east England regional Northern Accelerator Programme (Research England) in order to continue our studies into capturing proteins and protein-protein interactions using our novel tagging technology. Our plan is to commercialize the tagging technology within the biomedical / biotechnology sectors by developing an immobilized (bead-based) version of our tag aimed at the biologics market. We plan to be in a position to secure IP for our platform by the end 2020 / early 2021.
First Year Of Impact 2019
Sector Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology
Impact Types Societal,Economic

 
Description Northern Accelerator Award
Amount £45,397 (GBP)
Funding ID NA-CCF-32 
Organisation Durham University 
Sector Academic/University
Country United Kingdom
Start 01/2020 
End 12/2021
 
Title A new tool for recombinant protein purification 
Description This Tools and Resources Development Fund (TRDF) one year 'proof-of-concept' award into the development of 'A Novel Crosslinking Strategy for MS Structural Biology' has provided us with the funding to proof-of-concept, prototype and elaborate our novel tagging technology into a new paradigm for capturing protein-protein interactions (PPIs) as follows: 1. Enabled development of a prototype tagging methodology that displays highly specific (i.e. amino acid targeted) protein tagging. 2. The tagging supports mild chemical reaction conditions (e.g. phosphate buffer, pH 7.4) that permit capture of proteins (and their interaction partners) at neutral / near neutral pH, considered relatively benign for most protein-protein interactions. 3. The (chemical) tag cleavage mechanism has been designed to release protein (& interaction partners) under similarly mild conditions (~pH 8, bicarbonate buffer). In addition to capturing protein-protein interactions, this technology also shows promise in providing a new way to specifically (i.e. chemically) capture and release recombinant proteins under very mild (buffered) conditions that should preserve functionality and structure. At this time no 'chemica'l method for expressed protein purification exists, and so we can offer the first new 'class' of tool in the protein engineer's toolbox for a generation. All current tag purification methodologies on the market are based upon co-expressed amino acid fusion tags (such as polyhistidine, GST, FLAG, Strep-tag etc.) coupled with affinity capture and related elution chromatography. Affinity elution of tagged protein (the current norm) is replaced here by a mild chemical cleavage which serves to enrich the product without the need for increased stringency washes, a feature that provides new options for protein capture and release. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact This novel tool is currently under development with the aid of regional follow-on funding (Research England - Northern Accelerator Award) secured with the POC data accumulated during this project.Currently, our aim is to have our first prototype evaluated for IP protection by the end of 2020 / early 2021. We then intend to publish the method and/or seek a partner for commercialization of the tool.